More than 50 distinct point mutations in the kinase domain of BCR-ABL have been detected in patients with imatinib-resistant CML; point mutations in this domain are the most frequent cause of acquired imatinib resistance in CML patients [5,6]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.